Castle Biosciences Reports Second Quarter 2024 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Castle Biosciences (CSTL) PT Raised to $35 at BTIG
August 6, 2024 7:31 AM EDTBTIG analyst Sung Ji Nam raised the price target on Castle Biosciences (NASDAQ: CSTL) to $35.00 (from $32.00) while maintaining a Buy rating.
The analyst comments "Shares of CSTL are up 12% in the pre-market following a strong 25% Q2 revenue beat and raise to its... More
Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 58c, Beats on Revenue; Offers FY24 Revenue Guidance
August 5, 2024 4:20 PM EDTCastle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of $0.31, $0.58 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $87 million versus the consensus estimate of $69.37 million.
GUIDANCE:
Castle Biosciences Inc. sees FY2024 revenue of $275-300 million, versus the... More
